[A clinical study of PC-904 in pediatric field (author's transl)].
A clinical study of PC-904 was performed and the following results were obtained. 1) PC-904 was intravenously administered at the daily dosage of 20 approximately 120 mg/kg to 13 children; urinary tract infection (10 cases), acute pneumonia (1 case), sepsis (1 case) and purulent meningitis (1 case). The overall efficacy rate was 46.2%. 2) As to adverse reaction, eosinophilia was noted only in 2 patients. One neonate was treated with this drug, but no side effects were observed. 3) It was considered that PC-904 was a useful antibiotic drug for the second choice rather than the first.
D000208:Acute Disease; D000293:Adolescent; D000367:Age Factors; D000667:Ampicillin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007275:Injections, Intravenous; D008297:Male; D008581:Meningitis / Q000188:drug therapy; D009287:Naphthyridines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use; D011014:Pneumonia / Q000188:drug therapy; D018805:Sepsis / Q000188:drug therapy; D014552:Urinary Tract Infections / Q000188:drug therapy*
D009287:Naphthyridines; D000667:Ampicillin